July 29, 2016
Recommended Topic Related To:


"The US Food and Drug Administration (FDA) has approved adalimumab (Humira, AbbVie) for use in patients with noninfectious intermediate and posterior uveitis and panuveitis, the company announced.

Adalimumab is the first and o"...



How Supplied


ILEVRO (nepafenac ophthalmic suspension), 0.3% is indicated for the treatment of pain and inflammation associated with cataract surgery.


Recommended Dosing

One drop of ILEVRO (nepafenac ophthalmic suspension), 0.3% should be applied to the affected eye one-time-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. An additional drop should be administered 30 to 120 minutes prior to surgery.

Use With Other Topical Ophthalmic Medications

ILEVRO (nepafenac ophthalmic suspension), 0.3% may be administered in conjunction with other topical ophthalmic medications such as beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cycloplegics, and mydriatics.

If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart.


Dosage Forms And Strengths

Sterile Ophthalmic Suspension 0.3%

1.7 mL in a 4 mL bottle
3 mL in a 4 mL bottle

Storage And Handling

ILEVRO (nepafenac ophthalmic suspension), 0.3% is supplied in a white, oval, low density polyethylene DROP-TAINER® dispenser with a natural low density polyethylene dispensing plug and gray polypropylene cap presented in an overwrap (1.7mL fill only). Tamper evidence is provided with a shrink band around the closure and neck area of the package.

1.7 mL in 4 mL bottle NDC 0065-1750-07
3mL in 4 mL bottle NDC 0065-1750-14


Store at 2 - 25°C (36 - 77°F).

Protect from light.

Alcon Laboratories, Inc. Fort Worth, Texas 76134 USA. Rev: Feb 2014

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 12/14/2015

How Supplied

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

WebMD Daily

Get breaking medical news.